Want To Get Your Pharma Or Medtech Offer Adopted by the NHS in 2025? My New Newsletter Can Help Light The Way
The NHS has battled for years to find its footing after the Covid pandemic, and finally, it feels like there’s a foundational shift in progress.
If you’re working in pharma, medtech or devices, you’ve almost certainly felt it; new government, radical ideas, repositioned priorities.
The new NHS 10-Year Plan, for example, lays out a vision of a more integrated, prevention centred, community based NHS, rooted in neighbourhood teams, fuelled by data and innovation and laser focused on population health and good outcomes.
But behind the headlines, there’s an almost imperceptible shift in how industry sales teams now need to operate.
Striding into meetings with your shiny new product tucked under your arm hasn’t worked as a sales tactic for years, but now more than ever, your success completely depends on your prowess at showing the NHS your drug or device solves the problems they’re being held accountable for.
The Embedded Bulletin Takes You Right into the Rooms Where Deals Happened
There’s an art to that approach and, to help you understand it, I’ve launched a new fortnightly newsletter – The Embedded Bulletin.
I’ve been in the room when more than 80 NHS projects got the green light in the past two years alone, working alongside pharma, medtech and device teams to get offers over the line and properly embedded.
The Embedded Bulletin comes straight from inside those rooms. It’s for people who are tired of waiting on feedback that never comes, chasing projects that go nowhere and trying to second guess what decision makers actually want.
What The Embedded Bulletin Gives You
Each edition will cover what’s shifting in NHS policy, where the real opportunities are and how to align your offer so it lands.
And by ‘lands’ I don’t mean ‘secures a meeting’. I mean is funded, becomes embedded and then gets scaled.
You can expect the newsletter to tackle topics like:
- What “place based prevention” actually looks like in commissioning terms.
- How the Fuller Review is changing the GP landscape – and who you should now be talking to.
- Why features and benefits don’t cut it anymore (and what to show instead).
- What’s coming next in neighbourhood health, ICS delivery models and Integrated Health Organisation contracts.
Why You Need to Know This Stuff
The NHS is under pressure like never before, with more than £1.5bn in declared financial risk. That’s the estimated amount of planned financial efficiencies within the NHS now deemed unlikely to materialise, along with potential overspending against financial plans, as identified in NHS England’s financial assessments.
That doesn’t help the backlogs, workforce gaps and targets that can’t be missed.
If your offer doesn’t help solve that dilemma, it will crash and burn.
My newsletter gives you the insights you need to make sure that doesn’t happen.
Want to find the winning edge? Subscribe Today
If you work in pharma, medtech or devices – and want your work to actually make it in – get it in your inbox.
With 10 years in pharma and more than 20 working within the NHS, I bring a unique dual perspective, now captured in my upcoming book, launching September 2025, EMBEDDED: How Pharma, Medtech and Device Companies Can Get Their Products into NHS Pathways and Stay There. It distils everything I’ve learned into a practical playbook. Whether you’re launching a new product or trying to unlock stalled adoption, this book will show you how to reframe your offer, align with NHS priorities and make change stick.
You can read more about it here.